Transport of Zidovudine- and lamivudine-loaded polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate nanoparticles across the In vitro blood-brain barrier: Characteristics of the drug-delivery system

Journal of the Chinese Institute of Chemical Engineers

Volumn 36, Issue 6, 2005, Pages 627-638

  Kuo, Yung Chih ^a   Chung, Chiu Yen ^a  

^a NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

Blood brain barrier; Lamivudine; Methylmethacrylate sulfopropylmethacrylate; Nanoparticle; Polybutylcyanoacrylate; Zidovudine

Indexed keywords

BIOCHEMISTRY; BLOOD; BRAIN; CELLS; IMMUNOLOGY; NANOSTRUCTURED MATERIALS;

BLOOD-BRAIN BARRIER; LAMIVUDINE; METHYLMETHACRYLATE-SULFOPROPYLMETHACRYLATE; POLYBUTYLCYANOACRYLATE; ZIDOVUDINE;

DRUG PRODUCTS;

BIOCHEMISTRY; BLOOD; BRAIN; CELLS; DRUG PRODUCTS; IMMUNOLOGY; NANOSTRUCTURED MATERIALS;

EID: 32344446708     PISSN: 03681653     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Alyaudin, R. N., B. E. Tezikov, P. Ramge, D. A. Kharkevich, D. J. Begley, and J. Kreuter, "Significant Entry of Tubocurarine into the Brain of Rats by Adsorption to Polysorbate-80 Coated Polybutylcyanoacrylate Nanoparticles: An in situ Brain Perfusion Study," J. Microencapsul., 15, 67 (1998).
2. Audus, K. L. and R. T. Borchardt, "Characterization of an In Vitro Blood-Brain Barrier Model System for Studying Drug Transport and Metabolism," Pharm. Res., 3, 81 (1986).
3. Betz, A. L. and G. W. Goldstein, "The Basis for Active Transport at the Blood-Brain Barrier," Adv. Exp. Med. Biol., 131, 5 (1980).
4. Bowman, P. D., A. L. Betz, G. W. Goldstein, D. Ar, J. S. Wolinsky, J. B. Penney, and R. R. Shivers, "Primary Culture of Capillary Endothelium from Rat Brain," In Vitro, 17, 353 (1981).
5. Bowman, P. D., S. R. Ennis, K. E. Rarey, A. L. Betz, and G. W. Goldstein, "Brain Microvessel Endothelial Cells in Tissue Culture: A Model for Study of Blood-Brain Barrier Permeability," Ann. Neurol., 14, 396 (1983).
6. Bridges, E. G., G. E. Dutschman, E. A. Gullen, and Y. C. Cheng, "Favourable Interaction of β-L (-) Nucleoside Analogues with Clinically Approved Anti-HIV Nucleoside Analogues for Treatment of Human Immunodeficiency Virus," Biochem. Pharmacol., 51, 731 (1996).
7. Coates, J. A. V., N. Cammack, H. J. Jenkinson, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner, and J. M. Cameron, "(-) -2′-Deoxy-3′-Thiacytidine is a Potent, Highly Selective Inhibitor of Human Immunodeficiency Virus Type 1 and Type 2 Replication In Vitro," Antimicrob. Agents Chemother., 36, 733 (1992).
8. Debault, L. E., L. E. Kahn, S. P. Frommes, and P. A. Cancila, "Cerebral Microvessels and Derived Cells in Tissue Culture: Isolation and Preliminary Characterization," In Vitro, 15, 473 (1979).
9. Gelperina, S. E., Z. S. Smirnova, A. S. Khalansky, I. N. Skidan, A. I. Bobruskin, and J. Kreuter, "Chemotherapy of Brain Tumors Using Doxorubicin Bound to Polysorbate 80-Coated Nanoparticles," The 3rd World Meeting APV/APGI, p. 441, Berlin, Germany (2000).
10. Gelperina, S. E., A. S. Khalansky, I. N. Skidan, Z. S. Smirnova, A. I. Bobruskin, S. E. Severin, B. Turowski, F. E. Zanella, and J. Kreuter, "Toxicological Studies of Doxorubicin Bound to Polysorbate 80-Coated Poly(Butyl Cyanoacrylate) Naoparticles in Healthy Rats and Rats with Intracranial Glioblastoma," Toxicol. Lett., 126, 131 (2002).
11. Glynn, S. L. and M. Yazdanian, "In Vitro Blood-Brain Barrier Permeability of Nevirapine Compared to Other HIV Antiretroviral Agents," J. Pharm. Sci., 87, 306 (1998).
12. Gummerloch, M. K. and E. A. Neuwelt, "Drug Entry into the Brain and Its Pharmacologic Manipulation," Handbook of Experimental Pharmacology, Vol. 103, p. 525, M. W. B. Bradbury, Ed., Springer, Berlin, Germany (1992).
13. Hardebo, J. E. and J. Kahrstrom, "Endothelial Negative Surface Charge Areas and Blood-Brain Barrier Function," Acta Physiol. Scand., 125, 495 (1985).
14. Hillery, A. M., I. Toth, A. J. Shaw, and A. T. Florence, "Co-Polymerised Peptide Particles (CPP) I: Synthesis, Characterization and In Vitro Studies on a Novel Oral Nanoparticulate Delivery System," J. Control. Rel., 41, 271 (1996).
15. Hoffmann, F., J. Cinatl Jr., H. Kabicková, J. Cinatl, J. Kreuter, and F. Stieneker, "Preparation, Characterization and Cytoxicity of Methylmethacrylate Copolymer Nanoparticles with a Permanent Positive Surface Charge," Int. J. Pharm., 157, 189 (1997).
16. Katlama, C. and D. V. Havlir, "Newer Nucleosides: Lamivudine and Stavudine," AIDS, 10 (suppl A), s135 (1996).
17. Kreuter, J. and P. Speiser, "In Vitro Studies of Poly(Methyl Methacrylate) Adjuvants," J. Pharm. Sci., 65, 1624 (1976).
18. Kreuter, J., "Evaluation of Nanoparticles as Drug Delivery Systems. I. Preparation Methods," Pharm. Acta Helv., 58, 196 (1983).
19. Kreuter, J., R. N. Alyautdin, D. A. Kharkevich, and A. A. Ivanov, "Passage of Peptides through the Blood-Brain Barrier with Colloidal Polymer Particles (Nanoparticles)," Brain Res., 674, 171 (1995).
20. Kreuter, J., "Nanoparticulate Systems for Brain Delivery of Drugs," Adv. Drug Deliv. Rev., 47, 65 (2001).
21. Kuo, Y. C., "Loading Efficiency of Stavudine on Polybutylcyanoacrylate and Methylmethacrylate-Sulfopropylmethacrylate Copolymer Nanoparticles," Int. J. Pharm., 290, 161 (2005).
22. Langer, K., C. Marburger, A. Berthold, J. Kreuter, and F. Stieneker, "Methylmethacrylate Sulfopropylmethacrylate Copolymer Nanoparticles for Drug Delivery I: Preparation and Physiochemical Characterization," Int. J. Pharm., 137, 67 (1996).
23. Langer, K., E. Mutschler, G. Lambrecht, D. Mayer, G. Troschau, F. Stieneker and J. Kreuter, "Methylmethacrylate Sulfopropylmethacrylate Copolymer Nanoparticles for Drug Delivery. Part III: Evaluation as Drug Delivery System for Ophthalmic Applications," Int. J. Pharm., 158, 219 (1997).
24. Lipton, S. A., "Neuronal Injury Associated with HIV-1: Approaches to Treatment," Ann. Rev. Pharmacol. Toxicol., 38, 159 (1998).
25. Löbenberg, R., L. Araujo, H. von Briesen, E. Rodgers and J. Kreuter, "Body Distribution of Azidothymidine Bound to Hexylcyanoacrylate Nanoparticles after I. V. Injection to Rats," J. Control. Rel., 50, 21 (1998).
26. Masereeuw, R., U. Jaehde, M. W. Langemeijer, A. G. Deboer, and D. D. Breimer, "In Vitro and In Vivo Transport of Zidovudine (AZT) across the Blood-Brain Barrier and the Effect of Transport Inhibitors," Pharm. Res., 11, 324 (1994).
27. Meresse, S., M. P. Dehouck, P. Delorme, M. Bensaid, J. Tauber, C. Delbart, J. Fruchart and R. Cecchelli, "Bovine Brain Endothelial Cells Express Tight Junctions and Monoamine Oxidase Activity in Long-Term Culture," J. Neurochem., 53, 1363 (1989).
28. Otis, K. W., M. L. Avery, S. M. Broward-Partin, D. K. Hansen, H. W. Behlow Jr., D. O. Scott, and T. N. Thompson, "Evaluation of the BBMEC Model for Screening the CNS Permeability of Drugs," J. Pharmacol. Toxicol. Meth., 45, 71 (2001).
29. Panula, P., F. Joo, and L. Rechardt, "Evidence of the Presence of Viable Endothelial Cells in Cultures Derived form Dissociated Rat Brain," Experientia, 34, 95 (1978).
30. Phillips, P., P. Kumar, S. Kumar, and M. Waghe, "Isolation and Characterization of Endothelial Cells from Rat and Cow Brain White Matter," J. Analytics, 129, 261 (1979).
31. Saheki, A., T. Terasaki, I. Tamai, and A. Tsuji, "In Vivo and In Vitro Blood-Brain Barrier Transport of 3-Hydroxy-3-Methyl-Glutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors," Pharm. Res., 11, 305 (1994).
32. Schroeder, U., P. Sommerfeld, S. Ulrich and B. A. Sabel, "Nanoparticle Technology for Delivery of Drugs across the Blood-Brain Barrier," J. Pharm. Sci., 87, 1305 (1998).
33. 3H-Labelled Dalargin Bound to Poly(Butylcyanoacrylate) Nanoparticles after I. V. Injections to Mice," Life Sci., 66(6), 495 (2000).
34. Simon, V. A., M. D. Thiam, and L. C. Lipford, "Determination of Serum Levels of Thirteen Human Immunodeficiency Virus-Suppressing Drugs by High-Performance Liquid Chromatography," J. Chromatogr. A, 913, 447 (2001).
35. Soppimath, K. S., T. M. Aminabhavi, A. R. Kulkarni, and W. E. Rudzinski, "Biodegradable Polymeric Nanoparticles as Drug Delivery Devices," J. Control. Rel., 70, 1 (2001).
36. van Asperen, J., U. Mayer, O. van Tellingen, and J. H. Beijen, "The Functional Role of P-Glycoprotein in the Blood-Brain Barrier," J. Pharm. Sci., 86, 881 (1997).
37. Weyermann, J., D. Lochmann, C. Georgens, I. Rais, J. Kreuter, M. Karas, M. Wolkenhauer, and A. Zimmer, "Physicochemical Characterisation of Cationic Polybutylcyanoacrylat-Nanoparticles by Fluorescence Correlation Spectroscopy," Eur. J. Pharm. Biopharm., 58, 25 (2004).
38. Wu, D., J. G. Clement, and W. M. Pardridge, "Low Blood-Brain Barrier Permeability to Azidothymidine (AZT), 3TC™, and Thymidine in the Rat," Brain Res., 791, 313 (1998).
39. Yarchoan, R. R., W. Klecker, K. J. Weinhold, P. D. Markham, H. K. Lyerly, D. T. Durack, E. Gelman, S. Nusinhoff-Lehrman, R. M. Blum, R. W. Barry, G. M. Shearer, M. A. Fischl, H. Mitsuya, R. C. Gallo, J. M. Collins, D. P. Bolognesi, C. E. Meyers, and S. Broder, "Administration 3′-Azido, 3′-Deoxythymidine an Inhibitor of HTLV III/LAV Replication to Patients with AIDS and AIDS Related Complex," Lancet, 1, 575 (1986).
40. Yazdanian, M., "Blood-Brain Barrier Properties of Human Immunodeficiency Virus Antiretrovirals," J. Pharm. Sci., 88, 950 (1999).